C2230 | Cav2.2 channel blocker
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $60.00 | ||
| 25 mg | $225.00 |
C2230 (882243-88-1) is a novel Cav2.2 channel blocker (IC50 = 1.3 µM @ -50 mV; 10.2 µM @ -80 mV) with a unique binding mode (no GPCR-mediated inhibition). It displays preferential binding to the inactive state of the channel. C2230 is active in both rat and human DRG neurons. Active in rat models of neuropathic pain and mouse models of osteoarthritis. C2230 does not affect somatosensation or motor and cardiac function.
References/Citations:
- Tang et al. (2024), C2230, a preferential use- and state-dependent Cav2.2 channel blocker, mitigates pain behaviors across multiple pain models; J. Clin. Invest. Dec 10 e177429
C19H31NO3
>98% TLC
NMR: (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
C2230 (882243-88-1) is a novel Cav2.2 channel blocker (IC50 = 1.3 µM @ -50 mV; 10.2 µM @ -80 mV) with a unique binding mode (no GPCR-mediated inhibition). It displays preferential binding to the inactive state of the channel. C2230 is active in both rat and human DRG neurons. Active in rat models of neuropathic pain and mouse models of osteoarthritis. C2230 does not affect somatosensation or motor and cardiac function.
References/Citations:
- Tang et al. (2024), C2230, a preferential use- and state-dependent Cav2.2 channel blocker, mitigates pain behaviors across multiple pain models; J. Clin. Invest. Dec 10 e177429
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
